[BioPhenoMA Co., Ltd.] BioPhenoMA receives contract research contract for Parkinson’s disease diagnosis from Chase Therapeutics
BioPhenoMA Co., Ltd. Press release: September 26, 2024 BioPhenoMA receives contract research contract from Chase Therapeutics for Parkinson’s disease diagnosis BioPhenoMA receives contract research order from US drug discovery startup Chase Therapeutics to develop diagnostic biomarkers for Parkinson’s disease
https://prcdn.freetls.fastly.net/release_image/132552/4/132552-4-018e5533870a0b2a8d3d728a3ff8789c-3300×547.png
BioPhenoMA, Inc. (Shinjuku-ku, Tokyo, CEO: Naoto Fujii, hereinafter referred to as “BioPhenoMA”) has recently received contract research from Chase Therapeutics (Wachington, DC CEO: Tomas N, Chase, MD, hereinafter referred to as “Chase”), an American drug discovery startup. We have received an order. BioPhenoMA utilizes ultra-trace protein quantification technology TN-cyclon(TM) to support Chase’s development of diagnostic biomarkers for Parkinson’s disease. ■Research overview Parkinson’s disease, a neurodegenerative disease, is known to be caused by damage to nerve cells, but there are many unknowns about the detailed mechanism of onset, and there is a need for simple diagnostic techniques and biomarkers. Masu. In order to solve this market issue, Chase, whose CEO is Tomas N. Chase, a world-renowned neurologist, is conducting research and development of therapeutic drugs for Parkinson’s disease, as well as searching for biomarker substances suitable for diagnosis. We are doing This time, the potential of BioPhenoMA’s “TN-cyclon(TM)” and the “exosome analysis technology” that utilizes it has been highly evaluated, and BioPhenoMA has decided to begin research support in the form of contract research from Chase. It became. Through this activity, BioPhenoMA will accelerate business development using “TN-cyclon(TM)”. BioPhenoMA Co., Ltd.
https://www.biophenoma.com/ A startup (founded in April 2023) that has the core technology “TN-cyclon (TM)” that can detect and quantify extremely trace amounts of proteins, developed by Waseda University Professor Etsuro Ito and others. We believe that the detection and quantification of ultra-trace amounts of proteins are important for analyzing the mechanisms of biological phenomena. We are promoting research and development with the mission of “contributing to progress.” Chase Therapeutics
http://www.chasetherapeutics.com/ Since its founding in 2016, Chase Therapeutics has been a pioneer in drug development in the field of brain diseases. The company is focused on preventing central nervous system dysfunction and rapidly commercializing breakthrough treatments in neuroscience research. Key pipeline products include CTC-413, a palliative and neuroprotective treatment for Parkinson’s disease, and CTC-501, a treatment for major depression. Both drugs are currently under development along with CTC-611, a diagnostic drug for Parkinson’s disease. Chase Therapeutics is committed to improving the lives of all people suffering from neuropsychiatric disorders. Aims to Develop Diagnostic Biomarkers for Parkinson’s Disease BioPhenoMA Receives Contract Research Order from Chase Therapeutics, U.S. Drug Discovery Startup BioPhenoMA Inc. (Shinjuku-ku, Tokyo; CEO Naoto FUJII; hereinafter referred to as BioPhenoMA) has received a contract research order from Chase Therapeutics (Washinton, DC; CEO Tomas N, Chase, MD; hereinafter referred to as Chase), a drug discovery startup in the United States. BioPhenoMA will utilize its ultra-trace protein quantification technology, TN-cyclonTM, to support Chase’s development of diagnostic biomarkers for Parkinson’s disease. Outline of Research Parkinson’s disease, one of the most common neurodegenerative diseases, is known to be caused by neuronal damage. However, the pathogenesis of the disease is still under research, and there is a need for simple diagnostic techniques and biomarkers. Chase, led by world-renowned neurologist Thomas N.Chase, is addressing this market challenge by searching for suitable biomarker substances for diagnosis in parallel with research and development of therapeutics for Parkinson’s disease. This time, Chase evaluated the potential of TN-cyclonTM and its exosome analysis technology. Based on this evaluation, BioPhenoMA has decided to support this activity in the business form of research commissioned by Chase. BioPhenoMA will accelerate business development utilizing TN-cyclonTM through this activity. BioPhenoMA Inc.
https://www.biophenoma.com/ BioPhenoMA is a startup established in April 2023. Its core technology is TN-cyclon(TM), which Professor Etsuro Ito and his colleagues developed. This technology enables the easy and versatile detection and quantification of ultra-trace proteins. We believe that the detection and quantification of ultra-trace proteins are crucial for analyzing the mechanisms of biological phenomena. Therefore, we aim to “contribute to further progress in the biomedical field by creating an innovative platform that enables anyone to perform ‘ultra-trace protein detection’ anywhere easily” and are proceeding with technology applications. Chase Therapeutics
http://www.chasetherapeutics.com/ About Chase Therapeutics Chase Therapeutics Corporation, since its inception in 2016, has pioneered the discovery and development of needed
pharmaceuticals for brain disease. The company focuses on the rapid translation of therapeutic breakthroughs in neurosciences research that may help prevent and potentially cure central nervous system dysfunction. Lead drugs in its pipeline include CTC-413 for the palliative and neuroprotective treatment of Parkinson’s Disease and CTC-501 for Major Depressive Disorder. Both drugs, along with CTC-611, a diagnosis for Parkinson’s disease, are now in active development. Chase Therapeutics stands committed to improving the lives of all those afflicted by neuropsychiatric disease.
